(BEAT) Heartbeam - Overview
Stock: Ambulatory ECG, Vector Imaging, Cloud Software
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 104% |
| Relative Tail Risk | -26.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.27 |
| Alpha | -58.06 |
| Character TTM | |
|---|---|
| Beta | 1.007 |
| Beta Downside | 1.353 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.95% |
| CAGR/Max DD | -0.32 |
Description: BEAT Heartbeam February 05, 2026
HeartBeam, Inc. (NASDAQ: BEAT) is a U.S.–based medical-technology firm that creates ambulatory electrocardiogram (ECG) solutions, including three-dimensional vector imaging and a credit-card-sized, cloud-based diagnostic platform (AIMIGo) aimed at rapid heart-attack detection. The company was incorporated in 2015 and operates out of Santa Clara, California.
As of the latest Q4 2025 filing, HeartBeam reported revenue of approximately $12.5 million, a cash balance of $45 million, and a net loss of $5 million, reflecting ongoing investment in R&D and regulatory clearance efforts. The firm’s R&D spend rose to 28 % of revenue year-over-year, underscoring its focus on product development.
The ambulatory cardiac-monitoring market is expanding at a compound annual growth rate of roughly 8 % (2023-2028), driven by an aging U.S. population, higher prevalence of cardiovascular disease, and increasing reimbursement for remote monitoring under Medicare Advantage plans. These macro trends provide a tailwind for HeartBeam’s addressable market.
For a deeper quantitative comparison of HeartBeam’s valuation metrics, you might explore ValueRay’s analyst tools.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -5.36 > 0.02 and ΔFCF/TA -333.4 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -5.30 > 3% & CFO -15.2m > Net Income -20.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.4m) vs 12m ago 28.57% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -172.8 > 6 (EBITDA TTM -20.7m / Interest Expense TTM -120.0k) |
Altman Z'' -15.00
| A: -0.12 (Total Current Assets 2.13m - Total Current Liabilities 2.47m) / Total Assets 2.88m |
| B: -25.03 (Retained Earnings -72.0m / Total Assets 2.88m) |
| C: -4.35 (EBIT TTM -20.7m / Avg Total Assets 4.77m) |
| D: -29.14 (Book Value of Equity -72.0m / Total Liabilities 2.47m) |
| Altman-Z'' Score: -142.2 = D |
What is the price of BEAT shares?
Over the past week, the price has changed by -1.38%, over one month by -44.47%, over three months by -11.73% and over the past year by -41.39%.
Is BEAT a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BEAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.6 | 223.8% |
| Analysts Target Price | 4.6 | 223.8% |
| ValueRay Target Price | 1.4 | -5.6% |
BEAT Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -20.7m USD
EBITDA TTM = -20.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -1.86m USD (from netDebt column, last quarter)
Enterprise Value = 48.1m USD (49.9m + (null Debt) - CCE 1.86m)
Interest Coverage Ratio = -172.8 (Ebit TTM -20.7m / Interest Expense TTM -120.0k)
EV/FCF = -3.12x (Enterprise Value 48.1m / FCF TTM -15.4m)
FCF Yield = -32.06% (FCF TTM -15.4m / Enterprise Value 48.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 30.0k) / Revenue TTM)
Tobins Q-Ratio = 16.72 (Enterprise Value 48.1m / Total Assets 2.88m)
Interest Expense / Debt = unknown (Interest Expense 20.0k / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -16.4m (EBIT -20.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.86 (Total Current Assets 2.13m / Total Current Liabilities 2.47m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -1.86m / EBITDA -20.7m)
Debt / FCF = 0.12 (negative FCF - burning cash) (Net Debt -1.86m / FCF TTM -15.4m)
Total Stockholder Equity = 3.44m (last 4 quarters mean from totalStockholderEquity)
RoA = -432.6% (out of range, set to none)
RoE = -598.9% (Net Income TTM -20.6m / Total Stockholder Equity 3.44m)
RoCE = -5108 % (out of range, set to none) (EBIT -20.7m / Capital Employed (Total Assets 2.88m - Current Liab 2.47m))
RoIC = -475.9% (out of range, set to none) (NOPAT -16.4m / Invested Capital 3.44m)
WACC = 9.62% (E(49.9m)/V(49.9m) * Re(9.62%) + (debt-free company))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.30%
Fair Price DCF = unknown (Cash Flow -15.4m)
EPS Correlation: 44.39 | EPS CAGR: 12.67% | SUE: 0.81 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=+0.020 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.50 | Chg30d=+0.130 | Revisions Net=+1 | Growth EPS=+18.0% | Growth Revenue=+0.0%